BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dhalla AK, Al-Shamsie Z, Beraki S, Dasari A, Fung LC, Fusaro L, Garapaty A, Gutierrez B, Gratta D, Hashim M, Horlen K, Karamchedu P, Korupolu R, Liang E, Ong C, Owyang Z, Salgotra V, Sharma S, Syed B, Syed M, Vo AT, Abdul-Wahab R, Wasi A, Yamaguchi A, Yen S, Imran M. A robotic pill for oral delivery of biotherapeutics: safety, tolerability, and performance in healthy subjects. Drug Deliv Transl Res 2021. [PMID: 33604838 DOI: 10.1007/s13346-021-00938-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Kaffash E, Ali Shahbazi M, Hatami H, Nokhodchi A. An insight into gastrointestinal macromolecule delivery using physical oral devices. Drug Discov Today 2022:S1359-6446(22)00162-3. [PMID: 35460891 DOI: 10.1016/j.drudis.2022.04.014] [Reference Citation Analysis]
2 Vllasaliu D, Thanou M. Of devices and drugs - Ingestible bots for diagnosis and therapy. Adv Drug Deliv Rev 2022;183:114174. [PMID: 35217113 DOI: 10.1016/j.addr.2022.114174] [Reference Citation Analysis]
3 Gangaiah D, Ryan V, Van Hoesel D, Mane SP, Mckinley ET, Lakshmanan N, Reddy ND, Dolk E, Kumar A. Recombinant Limosilactobacillus ( Lactobacillus ) delivering nanobodies against Clostridium perfringens NetB and alpha toxin confers potential protection from necrotic enteritis. MicrobiologyOpen 2022;11. [DOI: 10.1002/mbo3.1270] [Reference Citation Analysis]
4 Tran H, ElSayed MEH. Progress and limitations of oral peptide delivery as a potentially transformative therapy. Expert Opin Drug Deliv 2022. [PMID: 35255753 DOI: 10.1080/17425247.2022.2051476] [Reference Citation Analysis]
5 Abramson A, Kirtane AR, Shi Y, Zhong G, Collins JE, Tamang S, Ishida K, Hayward A, Wainer J, Rajesh NU, Lu X, Gao Y, Karandikar P, Tang C, Lopes A, Wahane A, Reker D, Frederiksen MR, Jensen B, Langer R, Traverso G. Oral mRNA delivery using capsule-mediated gastrointestinal tissue injections. Matter 2022. [DOI: 10.1016/j.matt.2021.12.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
6 Cortegoso Valdivia P, Robertson AR, De Boer NKH, Marlicz W, Koulaouzidis A. An Overview of Robotic Capsules for Drug Delivery to the Gastrointestinal Tract. J Clin Med 2021;10:5791. [PMID: 34945087 DOI: 10.3390/jcm10245791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Pechenov S, Revell J, Will S, Naylor J, Tyagi P, Patel C, Liang L, Tseng L, Huang Y, Rosenbaum AI, Balic K, Konkar A, Grimsby J, Subramony JA. Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease. Sci Rep 2021;11:22521. [PMID: 34795324 DOI: 10.1038/s41598-021-01750-0] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
8 Chu JN, Traverso G. Foundations of gastrointestinal-based drug delivery and future developments. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34785786 DOI: 10.1038/s41575-021-00539-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
9 Awad A, Trenfield SJ, Pollard TD, Ong JJ, Elbadawi M, McCoubrey LE, Goyanes A, Gaisford S, Basit AW. Connected healthcare: Improving patient care using digital health technologies. Adv Drug Deliv Rev 2021;178:113958. [PMID: 34478781 DOI: 10.1016/j.addr.2021.113958] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 17.0] [Reference Citation Analysis]
10 Søgaard PP, Lind M, Christiansen CR, Petersson K, Clauss A, Caffarel-Salvador E. Future Perspectives of Oral Delivery of Next Generation Therapies for Treatment of Skin Diseases. Pharmaceutics 2021;13:1722. [PMID: 34684016 DOI: 10.3390/pharmaceutics13101722] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Byrne J, Huang HW, McRae JC, Babaee S, Soltani A, Becker SL, Traverso G. Devices for drug delivery in the gastrointestinal tract: A review of systems physically interacting with the mucosa for enhanced delivery. Adv Drug Deliv Rev 2021;177:113926. [PMID: 34403749 DOI: 10.1016/j.addr.2021.113926] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
12 Maher S, Brayden DJ. Formulation strategies to improve the efficacy of intestinal permeation enhancers. Adv Drug Deliv Rev 2021;177:113925. [PMID: 34418495 DOI: 10.1016/j.addr.2021.113925] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
13 Brayden DJ. The Centenary of the Discovery of Insulin: An Update on the Quest for Oral Delivery. Front Drug Deliv 2021;1:726675. [DOI: 10.3389/fddev.2021.726675] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Abramson A, Frederiksen MR, Vegge A, Jensen B, Poulsen M, Mouridsen B, Jespersen MO, Kirk RK, Windum J, Hubálek F, Water JJ, Fels J, Gunnarsson SB, Bohr A, Straarup EM, Ley MWH, Lu X, Wainer J, Collins J, Tamang S, Ishida K, Hayward A, Herskind P, Buckley ST, Roxhed N, Langer R, Rahbek U, Traverso G. Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors. Nat Biotechnol 2021. [PMID: 34462588 DOI: 10.1038/s41587-021-01024-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
15 Brayden DJ, Maher S. Transient Permeation Enhancer® (TPE®) technology for oral delivery of octreotide: a technological evaluation. Expert Opin Drug Deliv 2021;:1-11. [PMID: 34128734 DOI: 10.1080/17425247.2021.1942838] [Cited by in F6Publishing: 1] [Reference Citation Analysis]